PT  - JOURNAL ARTICLE
AU  - Langner, C
AU  - Ratschek, M
AU  - Rehak, P
AU  - Schips, L
AU  - Zigeuner, R
TI  - Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?
AID  - 10.1136/jcp.2003.015743
DP  - 2004 Jul 01
TA  - Journal of Clinical Pathology
PG  - 773--775
VI  - 57
IP  - 7
4099  - http://jcp.bmj.com/content/57/7/773.short
4100  - http://jcp.bmj.com/content/57/7/773.full
SO  - J Clin Pathol2004 Jul 01; 57
AB  - Aims: To assess whether heterogeneity of epidermal growth factor receptor (EGFR) immunoreactivity in renal cell carcinoma (RCC) is related to non-standardised criteria for staining evaluation. Methods: EGFR expression was investigated in 132 primary and 55 metastatic conventional RCCs using a tissue microarray technique. Results: Overall, membranous and/or cytoplasmic EGFR immunostaining was present in 123 of 132 (93%) primary and 49 of 53 (92%) metastatic RCCs, with extensive immunoreactivity (> 50% of tumour cells) in 110 of 132 (83%) primary tumours and 39 of 53 (73%) metastases. Cytoplasmic staining was associated with high tumour stage and high tumour grade. In addition, strong membranous staining (score 3+) prevailed in high grade RCCs. Cytoplasmic immunostaining was associated with an unfavourable prognosis, whereas overall (cytoplasmic and membranous) immunoreactivity and intensity of membranous staining were not. Conclusions: Different methods of immunohistochemical evaluation led to different results, strengthening the need for standardisation, especially against a background of rapidly evolving EGFR targeted cancer treatment strategies.